Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis

Abstract Objectives. The purpose of this study was to confirm the inhibitory effects of sunitinib, an angiogenesis inhibitor that targets tyrosine kinases of vascular endothelial growth factor receptor (VEGFR) family and platelet-derived growth factor receptor (PDGFR) family, on arthritis in mice with type II collagen-induced arthritis (CIA). Methods. Sunitinib at a concentration of 30 or 60 mg/kg/day was intraperitoneally administered to mice with CIA. We compared the changes in arthritis score over time, pathological score, bone density, and microvascular density in synovial membrane between the vehicle and treatment groups. Results. In the sunitinib-treated groups, the arthritis score decreased in a dose-dependent manner in comparison with that in the vehicle group. Furthermore, improvement in the pathological score, inhibitory tendency of loss in the bone density, and a decrease in the synovial microvascular density were also observed in the sunitinib-treated groups. Conclusions. Sunitinib remarkably inhibited arthritis, particularly synovial angiogenesis in a murine CIA model. This compound may be useful for treating arthritis.

[1]  E. Brahn,et al.  Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. , 1994, Cellular immunology.

[2]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[3]  M. Nishioka,et al.  Clinical Significance of Serum Levels of Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Patients with Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[4]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[5]  S. S. Lee,et al.  Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. , 2001, Clinical and experimental rheumatology.

[6]  M. Bokarewa,et al.  Inhibition of fms‐like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation , 2011, Journal of leukocyte biology.

[7]  M. Kawai,et al.  Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway , 2009, Modern rheumatology.

[8]  R. Roskoski,et al.  Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. , 2007, Biochemical and biophysical research communications.

[9]  J. Christensen,et al.  A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Hollema,et al.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. , 2011, Cancer research.

[11]  M. Pla,et al.  Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[12]  J. Hamilton,et al.  Exacerbation of acute inflammatory arthritis by the colony‐stimulating factors CSF‐1 and granulocyte macrophage (GM)‐CSF: evidence of macrophage infiltration and local proliferation , 2000, Clinical and experimental immunology.

[13]  A. Harris,et al.  The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis , 2001, The Journal of pathology.

[14]  K. Joh,et al.  Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis , 2003, Annals of the rheumatic diseases.

[15]  G. Martiny-Baron,et al.  Therapies directed at vascular endothelial growth factor , 2002, Expert opinion on investigational drugs.

[16]  K. Joh,et al.  The effect of endostatin evaluated in an experimental animal model of collagen‐induced arthritis , 2007, Scandinavian journal of rheumatology.

[17]  P. Kovanen,et al.  Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis , 2005, Annals of the rheumatic diseases.

[18]  S. Santavirta,et al.  Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. , 1998, The Journal of rheumatology.

[19]  B. Teh,et al.  Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. , 2010, Cancer research.

[20]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.